WCLC 2025 - Posters & ePosters-EP.08.42 A Prognostic Marker for Consolidation Therapy With Durvalumab After Concurrent Chemoradiotherapy in NSCLC: The Utility of Serum CYFRA 21-1

EP.08.42 A Prognostic Marker for Consolidation Therapy With Durvalumab After Concurrent Chemoradiotherapy in NSCLC: The Utility of Serum CYFRA 21-1

Back to course

Pdf Summary

This retrospective single-center study evaluated serum CYFRA 21-1 as a prognostic biomarker for patients with locally advanced non-small cell lung cancer (NSCLC) undergoing durvalumab consolidation therapy after concurrent chemoradiotherapy (cCRT). Durvalumab is a standard treatment for locally advanced NSCLC following cCRT, but reliable markers to predict prognosis during consolidation therapy are needed. Serum CYFRA, known for its sensitivity in detecting squamous cell carcinoma, was assessed alongside carcinoembryonic antigen (CEA) for their association with overall survival (OS) and progression-free survival (PFS).<br /><br />The study included 124 patients treated between July 2018 and November 2024. Patients were divided into high and normal serum CYFRA groups based on a threshold value of 3.5 ng/mL. Key findings showed that patients with high CYFRA levels had significantly worse median OS (45.5 months) compared to the normal CYFRA group (median OS not reached), with a hazard ratio (HR) of 2.12 (p=0.05). This prognostic association remained significant in multivariate analysis controlling for stage, histology, and other factors. Conversely, serum CEA levels showed no significant prognostic impact. Subgroup analyses restricted to non-squamous NSCLC also suggested a trend toward worse survival with high CYFRA, though not statistically significant.<br /><br />For PFS, high CYFRA patients had a shorter median progression-free interval (15.7 months) compared to normal CYFRA patients (31.5 months), but this difference did not reach statistical significance. The study demonstrates that serum CYFRA has potential utility as an independent prognostic biomarker for NSCLC patients receiving durvalumab consolidation after cCRT, irrespective of histological subtype or stage. This could help guide patient monitoring and therapeutic decisions in this setting.<br /><br />In summary, serum CYFRA 21-1 levels before cCRT serve as a significant prognostic marker for survival outcomes in locally advanced NSCLC treated with durvalumab, outperforming CEA and independent of tumor histology.

Asset Subtitle

Masahiro Ito

Meta Tag

Speaker Masahiro Ito

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

serum CYFRA 21-1

prognostic biomarker

locally advanced non-small cell lung cancer

durvalumab consolidation therapy

concurrent chemoradiotherapy

overall survival

progression-free survival

carcinoembryonic antigen

squamous cell carcinoma

multivariate analysis